德国国家儿童风湿病数据库:儿童及青少年风湿病患者SARS-CoV-2感染的临床表现与结局
该研究基于德国国家儿童风湿病数据库(NPRD),收集2020年4月17日至2021年2月16日期间76例实验室确诊SARS-CoV-2感染的儿童及青少年风湿病患者数据。多数患者病程轻、结局良好,84%的患者无风湿病活动度相关升高,但有一例需重症监护并死于心肺衰竭。
要点
- 儿童及青少年风湿病患者感染SARS-CoV-2后多数为轻症且结局良好。
- 84%的患者未观察到风湿病疾病活动度相关升高。
- 少数患者可发展为重症,本队列中一例死亡。
核心结论
- 儿童及青少年风湿病患者感染SARS-CoV-2后多数病程轻、结局良好,且对基础风湿病活动度无相关影响。
研究设计与样本
- 基于德国国家儿童风湿病数据库(NPRD)的特定SARS-CoV-2问卷,描述性分析76例实验室确诊SARS-CoV-2感染的儿童及青少年风湿病患者数据。
主要发现
- 76例患者中52%为女性,中位年龄14岁,诊断为幼年特发性关节炎(58%)、自身炎症性疾病(24%)和结缔组织病(8%)。
- 76%的患者接受改善病情抗风湿药(DMARDs)治疗,其中41%使用生物制剂DMARDs,11%使用全身性糖皮质激素。
- 76%的患者有COVID-19症状,多数病程为轻度和结局为恢复;两例住院,其中一例需重症监护并死于心肺衰竭。
- 84%的SARS-CoV-2阳性患者未观察到风湿病疾病活动度相关升高。
临床怎么用
- 儿童及青少年风湿病患者感染SARS-CoV-2后多数可按轻症管理,但需警惕少数重症可能。
- 感染SARS-CoV-2后多数患者风湿病活动度无相关升高,但仍需个体化监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to investigate the clinical manifestations, course and outcome of SARS-CoV-2 infection among children and adolescents with rheumatic and musculoskeletal diseases (RMD). Due to their underlying disease as well due to therapeutic immunosuppression, these patients may be at risk for a severe course of COVID-19 or for a flare of the underlying disease triggered by SARS-CoV-2 infection. METHODS: Demographic, clinical and treatment data from juvenile patients with RMD as well as data about SARS-CoV-2 infection like test date and method, clinical characteristics, disease course, outcome and impact on the disease activity of the RMD were documented on a specific SARS-CoV-2 questionnaire implemented in the National Paediatric Rheumatology Database (NPRD) in Germany. The survey data were analysed descriptively. RESULTS: From 17 April 2020 to 16 February 2021, data were collected from 76 patients (52% female) with RMD and laboratory-proven SARS-CoV-2 infection with median age of 14 years, diagnosed with juvenile idiopathic arthritis (58%), autoinflammatory (24%) and connective tissue disease (8%). Fifty-eight patients (76%) received disease-modifying antirheumatic drugs (DMARDs), 41% biological DMARDs and 11% systemic glucocorticoids. Fifty-eight (76%) had symptoms of COVID-19. Disease course of SARS-CoV-2 infection (classified as asymptomatic, mild, moderate, severe, life-threatening) was mild and outcome of COVID-19 (classified as recovered, not yet recovered, permanent damage or deceased) was good (recovered) in the majority of patients. Two patients were hospitalised, one of whom required intensive care and died of cardiorespiratory failure. In 84% of SARS-CoV-2-positive patients, no relevant increase in disease activity of the RMD was observed. CONCLUSIONS: In our cohort, SARS-CoV-2 infection in juvenile patients with RMD under various medications was mild with good outcome in the majority of cases and does not appear to have a relevant impact on disease activity of the underlying condition.
引用
- Sengler C, Eulert S, Minden K, et al. Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany. RMD Open. 2021. PMID: 34312307. doi:10.1136/rmdopen-2021-001687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。